TPG Capital, a global alternative asset firm, completed the acquisition of a majority stake in iNova, an independent consumer healthcare and medicine products company, from private equity firms Pacific Equity Partners and The Carlyle Group. Financial terms were not disclosed. "Our investment in iNova is timed as the world emerges from COVID-19 pandemic and consumers are increasingly mindful of preventative and early treatment across a range of symptoms, particularly upper respiratory, cold and flu," Joel Thickins, TPG Capital co-managing partner and head of Australia and New Zealand.